CD274 and melanoma: (1) revealed that the benefit of ICI treatment in advanced melanoma with NRAS mutation (NRAS-Mut) exceeded that in wildtype patients, especially from anti-PD-1/PD-L1 treatment (ORR 64% vs. 30%).